<DOC>
	<DOCNO>NCT00002258</DOCNO>
	<brief_summary>To determine safety , tolerability maximum tolerate dose SDZ ILE 964 administer daily subcutaneous injection patient infected human immunodeficiency virus ( HIV ) cytopenia ( low blood cell count ) . To obtain information biologic effect SDZ ILE 964 administration improve blood count HIV-infected patient . To obtain information effect SDZ ILE-964 administration parameter HIV replication residual immunologic function .</brief_summary>
	<brief_title>A Phase I , Open Label Trial Evaluate Safety , Tolerance Biological Effects SDZ ILE-964 ( Recombinant Human Interleukin-3 , RhIL-3 ) HIV Infected Patients With Cytopenia</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Leukopenia</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV seropositivity Western blot . Advanced ARC AIDS define CDC . Cytopenia define total peripheral leukocyte count &lt; 3,000 cells/mm3 platelet count &lt; 100,000 cells/mm3 serum hemoglobin &lt; 10 g/dl . Anticipated life expectancy = &gt; 6 month . Ambulatory . Willing sign inform consent . Willing forego use investigational therapy except ddI . Prior Medication : Allowed &gt; 2 week prior study entry : zidovudine . Allowed &gt; 4 week prior study entry : systemic cytotoxic chemotherapy ; investigational drug ; medication know myelosuppressive ganciclovir , trimethoprim/sulfamethoxazole dapsone . Allowed &gt; 6 week prior study entry : hemopoietic growth factor treatment GMCSF , EPO . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Active opportunistic infection . Symptoms CNS disease referable HIV infection . Dementia alter mental status would prohibit give understand informed consent . Systemic chemotherapy . Investigational therapy ddI . Medications know myelosuppressive effect ganciclovir , trimethoprim/sulfamethoxazole dapsone AZT . Other hematopoietic growth factor treatment GMCSF , GCSF , EPO . Prophylactic therapy pneumocystis oral thrush . ddI . Corticosteroids topical corticosteroid cream . Patients may : Life expectancy &lt; 6 month . Active drug alcohol abuse . Active opportunistic infection . Treatment investigational drug except ddI within 4 week study entry . Dementia alter mental state prohibits give informed consent . Symptoms CNS disease referable HIV infection . Major surgery within 4 week study entry . History major pulmonary cardiac disease . History prior malignancy Kaposi 's sarcoma noninvasive subcutaneous carcinoma . Documented allergic disorder asthma , history anaphylaxis , atopy , serum sickness , bronchospasm . Not allow within 2 week prior study entry : zidovudine ( AZT ) . Not allow within 4 week prior study entry : systemic cytotoxic chemotherapy ; investigational drug ddI ; medication know myelosuppressive ganciclovir , trimethoprim/sulfamethoxazole dapsone . Not allow within 6 week prior study entry : hematopoietic growth factor treatment GMCSC , GCSF , EPO . Radiation therapy major surgery within 4 week study entry . Active drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1992</verification_date>
	<keyword>Interleukin-3</keyword>
	<keyword>Recombinant Proteins</keyword>
	<keyword>Leukopenia</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Thrombocytopenia</keyword>
</DOC>